FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135847809> ?p ?o ?g. }

• W3135847809 abstract "Abstract Background England has experienced high rates of SARS-CoV-2 infection during the COVID-19 pandemic, affecting in particular minority ethnic groups and more deprived communities. A vaccination programme began in England in December 2020, with priority given to administering the first dose to the largest number of older individuals, healthcare and care home workers. Methods A cross-sectional community survey in England undertaken between 26 January and 8 February 2021 as the fifth round of the REal-time Assessment of Community Transmission-2 (REACT-2) programme. Participants completed questionnaires, including demographic details and clinical and COVID-19 vaccination histories, and self-administered a lateral flow immunoassay (LFIA) test to detect IgG against SARS-CoV-2 spike protein. There were sufficient numbers of participants to analyse antibody positivity after 21 days from vaccination with the PfizerBioNTech but not the AstraZeneca/Oxford vaccine which was introduced slightly later. Results The survey comprised 172,099 people, with valid IgG antibody results from 155,172. The overall prevalence of antibodies (weighted to be representative of the population of England and adjusted for test sensitivity and specificity) in England was 13.9% (95% CI 13.7, 14.1) overall, 37.9% (37.2, 38.7) in vaccinated and 9.8% (9.6, 10.0) in unvaccinated people. The prevalence of antibodies (weighted) in unvaccinated people was highest in London at 16.9% (16.3, 17.5), and higher in people of Black (22.4%, 20.8, 24.1) and Asian (20.0%, 19.0, 21.0) ethnicity compared to white (8.5%, 8.3, 8.7) people. The uptake of vaccination by age was highest in those aged 80 years or older (93.5%). Vaccine confidence was high with 92.0% (91.9, 92.1) of people saying that they had accepted or intended to accept the offer. Vaccine confidence varied by age and ethnicity, with lower confidence in young people and those of Black ethnicity. Particular concerns were identified around pregnancy, fertility and allergies. In 971 individuals who received two doses of the Pfizer-BioNTech vaccine, the proportion testing positive was high across all age groups. Following a single dose of Pfizer-BioNTech vaccine after 21 days or more, 84.1% (82.2, 85.9) of people under 60 years tested positive (unadjusted) with a decreasing trend with increasing age, but high responses to a single dose in those with confirmed or suspected prior COVID at 90.1% (87.2, 92.4) across all age groups. Conclusions There is uneven distribution of SARS-CoV-2 antibodies in the population with a higher burden in key workers and some minority ethnic groups, similar to the pattern in the first wave. Confidence in the vaccine programme is high overall although it was lower in some of the higher prevalence groups which suggests the need for improved communication about specific perceived risks. Two doses of Pfizer-BioNTech vaccine, or a single dose following previous infection, confers high levels of antibody positivity across all ages. Further work is needed to understand the relationship between antibody positivity, clinical outcomes such as hospitalisation, and transmission." @default.
• W3135847809 created "2021-03-15" @default.
• W3135847809 creator A5009796857 @default.
• W3135847809 creator A5012533867 @default.
• W3135847809 creator A5016609291 @default.
• W3135847809 creator A5018958802 @default.
• W3135847809 creator A5027773961 @default.
• W3135847809 creator A5034710571 @default.
• W3135847809 creator A5036168933 @default.
• W3135847809 creator A5038353299 @default.
• W3135847809 creator A5040480697 @default.
• W3135847809 creator A5044511006 @default.
• W3135847809 creator A5053088954 @default.
• W3135847809 creator A5058039821 @default.
• W3135847809 creator A5065381707 @default.
• W3135847809 creator A5066895396 @default.
• W3135847809 creator A5071392259 @default.
• W3135847809 creator A5076284681 @default.
• W3135847809 creator A5079625821 @default.
• W3135847809 creator A5079831627 @default.
• W3135847809 creator A5090829173 @default.
• W3135847809 creator A5091885439 @default.
• W3135847809 date "2021-03-01" @default.
• W3135847809 modified "2023-10-17" @default.
• W3135847809 title "REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England" @default.
• W3135847809 cites W2113945548 @default.
• W3135847809 cites W3042833857 @default.
• W3135847809 cites W3048683141 @default.
• W3135847809 cites W3090844627 @default.
• W3135847809 cites W3096786678 @default.
• W3135847809 cites W3111255098 @default.
• W3135847809 cites W3111590711 @default.
• W3135847809 cites W3111707573 @default.
• W3135847809 cites W3114818204 @default.
• W3135847809 cites W3126981244 @default.
• W3135847809 cites W3127288595 @default.
• W3135847809 cites W3127400850 @default.
• W3135847809 cites W3127450935 @default.
• W3135847809 cites W3131527546 @default.
• W3135847809 cites W3132313785 @default.
• W3135847809 cites W3135697461 @default.
• W3135847809 cites W4237721275 @default.
• W3135847809 cites W4249939890 @default.
• W3135847809 doi "https://doi.org/10.1101/2021.02.26.21252512" @default.
• W3135847809 hasPublicationYear "2021" @default.
• W3135847809 type Work @default.
• W3135847809 sameAs 3135847809 @default.
• W3135847809 citedByCount "37" @default.
• W3135847809 countsByYear W31358478092021 @default.
• W3135847809 countsByYear W31358478092022 @default.
• W3135847809 countsByYear W31358478092023 @default.
• W3135847809 crossrefType "posted-content" @default.
• W3135847809 hasAuthorship W3135847809A5009796857 @default.
• W3135847809 hasAuthorship W3135847809A5012533867 @default.
• W3135847809 hasAuthorship W3135847809A5016609291 @default.
• W3135847809 hasAuthorship W3135847809A5018958802 @default.
• W3135847809 hasAuthorship W3135847809A5027773961 @default.
• W3135847809 hasAuthorship W3135847809A5034710571 @default.
• W3135847809 hasAuthorship W3135847809A5036168933 @default.
• W3135847809 hasAuthorship W3135847809A5038353299 @default.
• W3135847809 hasAuthorship W3135847809A5040480697 @default.
• W3135847809 hasAuthorship W3135847809A5044511006 @default.
• W3135847809 hasAuthorship W3135847809A5053088954 @default.
• W3135847809 hasAuthorship W3135847809A5058039821 @default.
• W3135847809 hasAuthorship W3135847809A5065381707 @default.
• W3135847809 hasAuthorship W3135847809A5066895396 @default.
• W3135847809 hasAuthorship W3135847809A5071392259 @default.
• W3135847809 hasAuthorship W3135847809A5076284681 @default.
• W3135847809 hasAuthorship W3135847809A5079625821 @default.
• W3135847809 hasAuthorship W3135847809A5079831627 @default.
• W3135847809 hasAuthorship W3135847809A5090829173 @default.
• W3135847809 hasAuthorship W3135847809A5091885439 @default.
• W3135847809 hasBestOaLocation W31358478091 @default.
• W3135847809 hasConcept C126322002 @default.
• W3135847809 hasConcept C137403100 @default.
• W3135847809 hasConcept C144024400 @default.
• W3135847809 hasConcept C149923435 @default.
• W3135847809 hasConcept C159654299 @default.
• W3135847809 hasConcept C19165224 @default.
• W3135847809 hasConcept C203014093 @default.
• W3135847809 hasConcept C22070199 @default.
• W3135847809 hasConcept C2779134260 @default.
• W3135847809 hasConcept C2908647359 @default.
• W3135847809 hasConcept C3007834351 @default.
• W3135847809 hasConcept C3008058167 @default.
• W3135847809 hasConcept C512399662 @default.
• W3135847809 hasConcept C524204448 @default.
• W3135847809 hasConcept C71924100 @default.
• W3135847809 hasConcept C89623803 @default.
• W3135847809 hasConcept C99454951 @default.
• W3135847809 hasConceptScore W3135847809C126322002 @default.
• W3135847809 hasConceptScore W3135847809C137403100 @default.
• W3135847809 hasConceptScore W3135847809C144024400 @default.
• W3135847809 hasConceptScore W3135847809C149923435 @default.
• W3135847809 hasConceptScore W3135847809C159654299 @default.
• W3135847809 hasConceptScore W3135847809C19165224 @default.
• W3135847809 hasConceptScore W3135847809C203014093 @default.
• W3135847809 hasConceptScore W3135847809C22070199 @default.
• W3135847809 hasConceptScore W3135847809C2779134260 @default.
• W3135847809 hasConceptScore W3135847809C2908647359 @default.

• next